News | March 20, 2025
ZIM Laboratories receives marketing authorization for Dimethyl Fumarate in Portugal
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
The European regulator will conduct a re-inspection of the facility to verify the compliance
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
This e-commerce platform is launched as a hyperlocal model
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
There are 38.4 million people with diabetes in the United States
Subscribe To Our Newsletter & Stay Updated
